Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Cohen, S.B.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(3)
+
-
Other
(2)
+
-
Availability
Metadata Only
(5)
+
-
Creation Date
2011
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(5)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(5)
+
-
Author
Cohen, S.B.
(5)
+
-
Heijde, D. van der
(3)
+
-
Benda, B.
(2)
+
-
Breedveld, F.C.
(2)
+
-
Chai, A.
(2)
+
-
Connell, C.A.
(2)
+
-
Emery, P.
(2)
+
-
Genovese, M.C.
(2)
+
-
Gruben, D.
(2)
+
-
Keystone, E.
(2)
+
-
Keystone, E.C.
(2)
+
-
Kremer, J.M.
(2)
+
-
Matteson, E.L.
(2)
+
-
Nash, P.T.
(2)
+
-
ORAL Scan Investigators
(2)
+
-
Tanaka, Y.
(2)
+
-
Tegzova, D.
(2)
+
-
Wallenstein, G.
(2)
+
-
Wyman, B.
(2)
+
-
Zwillich, S.H.
(2)
+
-
Show more
Language
en
(5)
+
-
Search results
(1 - 5 of 5)
show grid
show list
save search
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: a 24-Month Phase 3 Study
SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB
AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS
